Poliomyelitis Drug Pipeline Analysis Report 2025

Poliomyelitis, commonly known as polio, is a highly contagious viral disease primarily affecting children under the age of five. The disease accounts for approximately 1 in every 200 infections leading to irreversible paralysis, with 5% to 10% of those paralyzed dying due to respiratory muscle paralysis. Despite advances in vaccination, there remains a significant unmet clinical need for better therapies, as current treatments mainly focus on managing symptoms rather than providing a cure. The growing emphasis on vaccine development and antiviral research is expected to drive substantial growth in the polio drug pipeline, offering new hope for more effective treatments in the future.

Report Coverage

The Poliomyelitis Drug Pipeline Insight Report by the publisher gives comprehensive insights into poliomyelitis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for poliomyelitis. The poliomyelitis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The poliomyelitis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with poliomyelitis treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to poliomyelitis.

Poliomyelitis Drug Pipeline Outlook

Poliomyelitis, or polio, is a highly infectious viral disease caused by the poliovirus, which primarily affects children under five. It spreads through contaminated water or food, and, in severe cases, leads to paralysis or death. The poliovirus attacks the nervous system, damaging motor neurons that control muscles.

Poliomyelitis treatment involves supportive care to alleviate symptoms. The primary prevention method is vaccination, with the inactivated poliovirus vaccine (IPV) and oral poliovirus vaccine (OPV) providing effective immunity against the virus.

Poliomyelitis Epidemiology

A 2024 report on circulating vaccine-derived poliovirus (cVDPV) cases highlights key epidemiological trends in the ongoing fight against poliomyelitis. In 2023, 522 cases were confirmed, with 43% of them occurring in the Democratic Republic of the Congo. The decreasing number of cVDPV2 emergence groups, including 14 derived from the novel oral polio vaccine type 2 (nOPV2), reflects progress in controlling poliomyelitis transmission. However, the detection of cVDPV in the environment, notably in Nigeria and other countries, underscores the importance of continued poliomyelitis surveillance and the development of effective vaccines and treatments to mitigate future risks.

Poliomyelitis Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of poliomyelitis drug candidates based on several segmentations, including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Small Molecules
• Monoclonal Antibodies
• Gene Therapy
• Biologics
• Immunomodulators

By Route of Administration

• Oral
• Parenteral
• Others

Poliomyelitis Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total poliomyelitis clinical trials.

Poliomyelitis - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the poliomyelitis pipeline analysis include small molecules, monoclonal antibodies, gene therapy, biologics, and immunomodulators. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for poliomyelitis.

Poliomyelitis Clinical Trials Therapeutic Assessment - Competitive Dynamics

The poliomyelitis drug report insights include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in poliomyelitis clinical trials:

• Serum Institute of India Pvt. Ltd.
• LG Chem
• CanSino Biologics Inc.
• Bio Farma
• Sinovac Biotech Co., Ltd.
• DiagnoSearch Life Sciences Pvt. Ltd.
• Istari Oncology, Inc.
• Technical Resources International, Inc.
• Istari Oncology, Inc.

Poliomyelitis Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for P\poliomyelitis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of poliomyelitis drug candidates.

Biological: sIPV

Sinovac Biotech Co., Ltd. is sponsoring a Phase 4 clinical trial to assess the immunogenicity and safety of a booster dose of the Sabin strain inactivated poliovirus vaccine (sIPV) co-administered with MMR and HepA-I vaccines. The study will involve around 960 participants and is expected to be completed by March 2025, focusing on vaccine efficacy and safety.

Biological: Hexavalent (DTwP-HepB-IPV-Hib) vaccine containing reduced dose IPV

The clinical study, sponsored by Serum Institute of India Pvt. Ltd., aims to assess the immunogenicity and safety of a hexavalent vaccine containing a reduced dose of inactivated polio vaccine (IPV) for poliomyelitis. The study is expected to be completed by May 2026 and will involve 1,557 healthy infants and toddlers, with a primary completion date set for August 2025.

Biological: Recombinant trivalent poliomyelitis vaccine (Sf-RVN Cell) (VLP-Polio) low adjuvant dose

A Phase 1/2 randomized, double-blind study sponsored by CanSino Biologics Inc. aims to evaluate the safety and immunogenicity of the virus-like particle poliomyelitis vaccine in infants and toddlers. Participants will receive varying doses of the investigational vaccine. The study, expected to be completed by December 2026, will involve an estimated 480 participants. Blood and mucosal samples will be analyzed for immunogenicity.

Reasons To Buy This Report

The Poliomyelitis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for poliomyelitis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within poliomyelitis pipeline insights.

Key Questions Answered in the Poliomyelitis - Pipeline Insight Report

• Which companies/institutions are leading the poliomyelitis drug development?
• What is the efficacy and safety profile of poliomyelitis pipeline drugs?
• Which company is leading the poliomyelitis pipeline development activities?
• What is the current poliomyelitis commercial assessment?
• What are the opportunities and challenges present in the poliomyelitis drug pipeline landscape?
• What is the efficacy and safety profile of poliomyelitis pipeline drugs?
• Which company is conducting major trials for poliomyelitis drugs?
• Which companies/institutions are involved in poliomyelitis collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in poliomyelitis?

This product will be delivered within 3-5 business days.